• About
  • Subscribe
  • Advertise
  • Contact
Saturday, May 17, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

Carrera’s Australia performance highlighted in ‘solid’ Q1 2025 for Safilo

by Staff Writer
May 9, 2025
in Company updates & acquisitions, Local, News, Ophthalmic insights
Reading Time: 3 mins read
A A
CEO Angelo Trocchia said 2025 had started with “encouraging momentum”. Image: Safilo.

CEO Angelo Trocchia said 2025 had started with “encouraging momentum”. Image: Safilo.

Share on FacebookShare on Twitter

Asia-Pacific was the strongest performing region for Safilo in terms of sales growth in the first three months of 2025, with the Carrera eyewear brand’s “good progression in Australia” a highlight in the region’s €14.4 million (AU$25.2 m) quarter.

Globally, the group – a popular eyewear supplier among independent Australian optical practices – reported a “return to sales growth and solid financial performance in an uncertain environment” in Q1 2025. Net sales reached €285.8 million (AU$501.7 m), a 2.2% increase at constant exchange rates.

The Asia-Pacific Q1 2025 result – which realised positive results from initiatives like Carrera’s collaboration with Australian cricket captain Mr Pat Cummins – was up 18.5% at constant exchange rates and 21.2% at current exchange rates.

“The performance of the area benefited from Carrera’s good progression in Australia, thanks to effective co-branding initiatives and the rollout of the women’s collection,” the company stated.

“In addition, the Asian market was positively impacted by a more favourable shipping time for some orders from key accounts and distributors.”

Asia-Pacific’s growth was considerably higher than other regions Safilo operates in, with Europe recording 2.8% revenue growth to €128.9 million (AU$226 m), North America up 1% to €118.8 million (AU$208 m) and Rest of World down 2.9% to €23.7 million (AU$40 m).

Safilo CEO Mr Angelo Trocchia said 2025 had started with “encouraging momentum”, particularly in January when North America built on the positive recovery trends seen at the close of 2024.

“During the quarter uncertainty increased with escalating geopolitical tensions gradually impacting customer confidence,” he said.

“In this complex context, we delivered a solid first quarter. Europe continued to be where our innovation and customer focus aligned most effectively, helping to drive broad-based growth across markets and brands.”

Sales performance was positive across most brands in the group’s portfolio. In particular, the company said its Smith band “further strengthened its leadership” in the North American market for ski goggles and helmets, while Carrera and David Beckham consolidated the strong momentum already seen throughout 2024.

According to Safilo, the quarter was also marked by growth for Polaroid, building on the recovery seen in the fourth quarter of 2024, and for key licensed brands, from Tommy Hilfiger and Carolina Herrera, to BOSS, HUGO and Marc Jacobs.

Gross profit in Q1 2025 totalled €173 million (AU$303 m), growing by 4.1% compared to Q1 2024. Gross margin increased by 50 basis points, from 60.0% to 60.5%.

From a financial standpoint, Trocchia said the group achieved “solid growth across all margins and delivered a strong acceleration in cash generation”.

“As the tariff landscape continues to evolve, we maintain a prudent and flexible approach, leveraging the current challenges to accelerate the diversification of our supply chain,” he said.

“Our commitment to long-term brand building, operational agility, and financial resilience remains unchanged.”

More reading

Carrera Eyewear, Aussie cricket captain Cummins continue partnership

Safilo reports $1.6b revenue in 2024

Empowering independents: CR Labs and Safilo expand Full Circle Program

Related Posts

Dr Lourens van Zyl recently switched to Blink eye drops in his clinic. Images: B+L.

Bausch + Lomb’s blinking success

by Staff Writer
May 17, 2025

Every second counts in Dr Lourens van Zyl’s busy Perth clinic, motivating him to switch to a new lubricating eye...

The cost of intravitreal eye injections to manage macular degeneration can discourage many older Australians from continuing treatment. Image: Rose Makin/stock.adobe.com.

Special Report: Intravitreal injections and bulk billing – good for business

by Rob Mitchell
May 16, 2025

Frequent intravitreal injections are vital to help many older Australians keep their eyesight, but the costs can be prohibitive. Insight...

A scene from the movie My Eyes, featuring optometrist Tsu Shan Chambers (right). Image: FanForce Films.

My Eyes film starring Australian optometrist set to open in theatres

by Staff Writer
May 16, 2025

A film highlighting the remarkable journey of a Australian mother determined to save her daughter’s eyesight, and starring a practising...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited